U.S. President-elect Donald Trump's pro-crypto stance is prompting small businesses to allocate portions of their cash to bitcoin, challenging the dominance of traditional assets as companies look for more robust inflation hedges. Over the past month, biotech firms Enlivex Therapeutics, Acurx Pharmaceuticals and Hoth Therapeutics have set a target of purchasing up to $1 million of bitcoin to hold as a treasury reserve asset. The moves underscore the growing appeal of bitcoin as a legitimate tool for corporate treasurers, who see it as a better alternative in a landscape fraught with economic uncertainty, geopolitical risks and fiscal concerns that have complicated the outlook for conventional assets like Treasuries and cash.